Preferences of patients with high-risk HR + /HER2- breast cancer for adjuvant endocrine treatment: an adaptive choice-based conjoint analysis study from Germany
Reduction of tumour recurrence was the attribute of highest relative importance for patients with high-risk HR + /HER2- EBC followed by side effect avoidance and quality-of-life maintenance, reflecting their importance in treatment decisions.
Authors
- Kirsten Raab
- Achim Wöckel (ORCID: https://orcid.org/0000-0002-6767-9666)
- Hans Tesch (ORCID: https://orcid.org/0000-0001-7839-4917)
- Tjoung‐Won Park‐Simon (ORCID: https://orcid.org/0000-0002-2863-3040)
- Agnieszka Korfel
Institutions
- Medizinische Hochschule Hannover (DE)
- Cardiovascular Center Bethanien (DE)
- Eli Lilly (Germany) (DE)
- Universitätsklinikum Würzburg (DE)
Publication Details
- Journal
- Breast Cancer Research and Treatment
- Published
- 2025-02-20
- DOI
- https://doi.org/10.1007/s10549-025-07622-9
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company